Business Description
![Noxopharm Ltd Noxopharm Ltd logo](https://static.gurufocus.com/logos/0C0000B4H1.png?14)
Noxopharm Ltd
ISIN : AU000000NOX9
Description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | -194.3 | |||||
3-Year FCF Growth Rate | 23 | |||||
3-Year Book Growth Rate | -19.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.84 | |||||
9-Day RSI | 51.1 | |||||
14-Day RSI | 49.11 | |||||
6-1 Month Momentum % | -2.44 | |||||
12-1 Month Momentum % | 86.05 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.79 | |||||
Quick Ratio | 12.79 | |||||
Cash Ratio | 10.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.1 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -105.92 | |||||
ROA % | -92.81 | |||||
ROIC % | -204.85 | |||||
ROC (Joel Greenblatt) % | -1276.03 | |||||
ROCE % | -104.15 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.18 | |||||
Price-to-Tangible-Book | 3.5 | |||||
EV-to-EBIT | -0.78 | |||||
EV-to-EBITDA | -0.78 | |||||
EV-to-FCF | -1.34 | |||||
Price-to-Net-Current-Asset-Value | 3.5 | |||||
Price-to-Net-Cash | 3.5 | |||||
Earnings Yield (Greenblatt) % | -128.67 | |||||
FCF Yield % | -29.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Noxopharm Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.042 | ||
Beta | -0.67 | ||
Volatility % | 172.13 | ||
14-Day RSI | 49.11 | ||
14-Day ATR (A$) | 0.00323 | ||
20-Day SMA (A$) | 0.0706 | ||
12-1 Month Momentum % | 86.05 | ||
52-Week Range (A$) | 0.033 - 0.165 | ||
Shares Outstanding (Mil) | 292.24 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Noxopharm Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Noxopharm Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Noxopharm Ltd Frequently Asked Questions
What is Noxopharm Ltd(ASX:NOX)'s stock price today?
The current price of ASX:NOX is A$0.07. The 52 week high of ASX:NOX is A$0.17 and 52 week low is A$0.03.
When is next earnings date of Noxopharm Ltd(ASX:NOX)?
The next earnings date of Noxopharm Ltd(ASX:NOX) is .
Does Noxopharm Ltd(ASX:NOX) pay dividends? If so, how much?
Noxopharm Ltd(ASX:NOX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |